Frontlight ResearchEarly access
CompletedPhase 3
Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms
Key facts
- Who runs it
- Hoffmann-La Roche
- Where
- China16 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 100 people enrolled
- Started
- 27 Oct 2024
- Ended
- 8 May 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Baloxavir Marboxil
- Oseltamivir
- Record updated
- 27 April 2026
Who can take part
- Age
- 1 year to 11 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- A participant who has a diagnosis of influenza virus infection and meets all the following conditions:; Fever ≥ 38°C (tympanic temperature) at screening; At least one of the respiratory symptoms of influenza virus infection
- A rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) shows positive for influenza A/B, e.g., point-of-care/local laboratory results with use of nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)
- The time interval between the onset of symptoms and screening is ≤ 48 hours
- PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care/local laboratory test with nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)
Who cannot take part
- Received systemic corticosteroid or immunosuppressive therapy
- Immunization with a live/attenuated influenza vaccine in 2 weeks prior to randomization
- A participant who received any medications with anti-flu effect such as baloxavir, peramivir, oseltamivir, zanamivir, favipiravir, arbidol, amantadine or traditional Chinese anti-influenza medicines within 30 days before screening
- A participant who received an investigational or unapproved drug product within 30 days or 5 x the half-life before screening, whichever is longer
- A participant having severe influenza virus infection symptoms requiring inpatient treatment
- Primary immunodeficiency syndrome
- History of organ transplantation
- Human immunodeficiency virus (HIV) infection
- Previous malignancy within the last 5 years or has an active cancer at any site
- Diagnosed with or suspected SARS-CoV-2 infection, or close contacts of diagnosed or suspected SARS-CoV-2 infected patients
- Severe underlying disease or condition potentially affecting study evaluation in the opinion of the investigator/sub-investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to < 12 years with influenza symptoms.
The 2 groups in the trial
- Baloxavir MarboxilTreatment being tested
Participants will receive a single oral dose of baloxavir marboxil on Day 1 based on body weight.
- OseltamivirExisting treatment, for comparison
Participants will receive oseltamivir twice a day for 5 days based on body weight.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms
- Record updated
- 27 April 2026